论文部分内容阅读
目的:总结新型冠状病毒肺炎（COVID-19）患者救治中抗凝治疗应用的经验。方法:分析2020年1月至2020年2月武汉协和医院收治的3例COVID-19病例的临床资料。3例患者均在住院一周内病情恶化，呼吸困难加重，且血浆D-二聚体水平显著升高（>20 mg/L），其中男性2例，使用依诺肝素钠抗凝，女性1例，初始使用低分子肝素钠抗凝，停用后续接依诺肝素钠抗凝。结果:3例患者在给予抗凝治疗后，呼吸症状随之缓解，且无血栓事件发生。结论:COVID-19患者多合并静脉血栓栓塞症的高危因素，积极的抗凝治疗不仅可以预防血栓形成，同时可能改善患者预后。“,”Objective:To summarize the experience of anticoagulant therapy in patients with COVID-19.Methods:The clinical data of 3 special patients confirmed COVID-19 in January and February 2020 in Union Hospital of Tongji Medical College, Huazhong University of Science and Technology were analyzed. All the three patients had worsened condition, worsened respiratory symptoms and significantly increased plasma D-dimer level (>20 mg/L) within one week of hospitalization. Two male patients were treated with enoxaparin sodium. Another female was treated with low molecular weight heparin sodium, followed by enoxaparin sodium.Results:Respiratory symptoms were relieved after prophylactic anticoagulation treatment. And no thrombotic events occurred.Conclusions:Patients with COVID-19 are associated with high risk factors for venous thromboembolism. Prophylactic anticoagulation may not only prevent thrombosis, but also improve the prognosis of patients.